Industry Outlook

The Diabetes Care Devices market accounted for USD 36.7 Billion in 2024 and is expected to reach USD 95.6 Billion by 2035, growing at a CAGR of around 9.1% between 2025 and 2035. Diabetes Care Devices market encompasses a collection of medical instruments used to manage diabetes. These devices include insulin pens, insulin pumps, glucose meters, and continuous glucose monitoring systems (CGM). They enable individuals to check their blood glucose levels, take insulin, and keep track of complete diabetes management. Increasing rates of diabetes, technological developments, and a growing need for effective solutions are the factors driving this market. Furthermore, data integration and device connectivity are changing the way this industry develops.

Report Scope:

Market Dynamics

Rising prevalence of diabetes globally due to lifestyle changes and aging populations

Diabetes is becoming common worldwide as a result of aging populations and changing lifestyles, which has led to an increase in diabetes care devices market. Lifestyle and environmental factors, such as sedentary lifestyles, poor dietary habits, and rising obesity rates, are the causes of type 2 diabetes. In addition, older individuals are at greater risk of developing diabetes, hence necessitating continuous monitoring and management services. Technological improvements like continuous glucose monitors (CGMs) and insulin pumps help improve patient outcomes. According to the World Health Organization (WHO), 422 million people worldwide suffer from diabetes, and the number of cases is increasing in low- and middle-income nations. These elements stimulate the expansion of demand for diabetes care devices worldwide.

Strict regulatory requirements for approval, lead to delays in product launches

Strict standards are set by authorities that must be satisfied before new devices are approved. This approval process is a major barrier to the diabetes care device market. Continuous glucose monitors, insulin pumps, and blood glucose meters must meet the safety and efficacy standards established by government health organizations, such as the US FDA, EMA in Europe, and other government regulatory authorities. Furthermore, companies face additional challenges in supplying a new device, especially if they comply with multiple regulatory agencies and their respective guidelines. Businesses must invest capital for the new requirements to meet the regulations. These restrictions make it more difficult for smaller firms to develop products, leading to an uncompliant course of action and less competition for already established businesses.

Expansion of telemedicine and remote monitoring, enabling better diabetes management in remote areas

Diabetes Care Devices Market has tremendous potential, especially in rural and underserved areas where telemedicine's remote monitoring system and quick expansion have new opportunities. Patients can consult their healthcare providers with telemedicine allows continuous follow-up and prompt treatment. This is very important in diabetes management, where glucose levels are regularly checked and insulin dose is adjusted. Devices like continuous glucose monitors (CGMs) and smart insulin pens can transmit data to medical practitioners, leading to improved medication adherence and increased ability to deliver specialized care.

Industry Experts Opinion

“Anti-obesity medications may play a role in bridging the gap between what we can achieve with lifestyle treatments and more invasive procedures like bariatric surgery,”

• Dr. S. Yanovski, Co-Director, Office of Obesity Research, National Institute of Diabetes and Digestive and Kidney Diseases.

“Diabetes management is complex and personal for every individual. By combining technology with a deep understanding of the challenges that people living with diabetes face, we seek to enable them to navigate the daily complexities of diabetes management with confidence. The future of diabetes care lies in personalization, connectivity, and collaboration for healthcare sustainability.”

• Bryan Koh, Cluster Head of Asia Pacific Mature Markets, Roche Diabetes Care.

Segment Analysis

Based on the product type, Diabetes Care Devices Market is classified into Blood Glucose Monitoring Devices [Continuous Glucose Monitoring Systems and Self-Monitoring Blood Glucose Systems] and Treatment Devices [Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, and Others]. The Blood Glucose Monitoring Device segment is dominant in the Diabetes Care Device Market. Continuous Glucose Monitoring Systems (CGMS) are prominent because they provide instant glucose readings and reduce the need for finger sticks to take blood samples. This instant data helps to manage their glucose better and avoid developing complications due to the disease, and this remains an essential tool for diabetic patients. The adoption rate for CGMS indicates how important it is to manage diabetes disease. 

Based on the technology, Diabetes Care Devices Market is classified into Wearable Devices and Non-Wearable Devices. Wearable devices are the largest and most prominent segment. Includes insulin pumps and continuous glucose monitoring devices that measure blood glucose and provide real-time feedback. Such devices are popular because they allow the automatic delivery of insulin, improve blood sugar control among those suffering from diabetes, and encourage patients. The greater use of this technology plays an important role in individual management of diabetes mellitus.

Regional Analysis

Diabetes Care Devices Market is leading in North America due to an increase in cases of diabetes, development in technology, and increased awareness about healthcare. This market is demonstrated by the high adoption rate for sophisticated diabetes management tools like insulin pumps and continuous glucose monitors (CGMs). To introduce new products and improve available devices, major players have investments in research and development (R&D). Besides this, other factors that have allowed North American markets to continue growing positively are various kinds of regulations and advantageous reimbursement practices.

In Europe, the Diabetes Care Devices Market is experiencing significant growth. Diabetes recurrence is increasing the need for advanced management solutions. The market has various devices like continuous glucose monitors (CGM), insulin pumps, and smart insulin pens that are triggered by technological advancements and growing patient preferences to personalize therapy. Countries in Europe are experiencing higher levels of adoption of digital health solutions and integrated diabetes management systems. The regulatory frameworks and payment guidelines across different countries have an impact on market growth and accessibility. Overall, this sector has adopted new technologies to ensure a good quality of life for people living with diabetes.

Competitive Landscape

The diabetes care devices market is highly competitive due to the occurrence of new diabetes cases and technological development. Some key players include Abbvie Laboratories, Medtronic, Roche Diabetes Care, and Dexcom, Inc. with their sophisticated insulin pumps, continuous glucose monitoring (CGM) systems, as well as smart insulin delivery devices. Abbott's FreeStyle Libre and Dexcom's G7 CGM utilize real-time testing of blood sugar values that allow better diabetes management. Recently Medtronic released the MiniMed 780G, a new, advanced automated insulin pump, while Tandem Diabetes Care added a bolus option to their tX2 insulin pump that can be operationalized via a mobile device.

Diabetes Care Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2023, a startup called My Diabetes Tutor, which aims to enhance the lives of people with diabetes, received joint funding from CharmHealth and Bioverge.
• In May 2023, Medtronic agreed to acquire insulin device manufacturer EOFlow. EOFlow's integration with Medtronic's sophisticated continuous glucose monitor (CGM) and Meal Detection Technology algorithm is anticipated to improve the company's capacity to assist a wider spectrum of diabetics.
• In April 2023, Undbio declared its intention to invest USD 100 million in building an insulin manufacturing facility in the United States. The South Korean company wants to construct a new facility in West Virginia so that it can produce and sell insulin domestically.

Report Coverage:

By Product Type

• Blood Glucose Monitoring Devices        

• Continuous Glucose Monitoring Systems
• Self-Monitoring Blood Glucose Systems

• Treatment Devices

• Insulin Pens
• Insulin Pumps
• Insulin Jet Injectors
• Insulin Syringes
• Others

By Technology

• Wearable Devices
• Non-Wearable Devices

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

By End-User

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Home Care

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic plc
• Abbott Laboratories
• Roche Diabetes Care
• Dexcom, Inc.
• Ascensia Diabetes Care Holdings AG
• Insulet Corporation
• Novo Nordisk A/S
• Sanofi
• Tandem Diabetes Care, Inc.
• Ypsomed AG
• Becton, Dickinson and Company
• Senseonics Holdings, Inc.
• Eli Lilly and Company
• LifeScan, Inc.
• GlucoMe

Frequently Asked Questions (FAQs)